Recently released market study: Benign Prostatic Hyperplasia - Pipeline Review, H2 2013

Global Markets Direct's, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. Benign Prostatic Hyperplasia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- http://www.fastmr.com/prod/675219_benign_prostatic_hyperplasia_pipeline_review_h2.aspx?afid=301

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia.
* A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Eli Lilly and Company, Light Sciences Oncology, Inc., Ipsen S.A., Aphios Corporation, Astellas Pharma Inc., Chong Kun Dang Pharmaceutical, Dong-A Pharmaceutical Co., Ltd., Addex Pharmaceuticals, AEterna Zentaris Inc., IntelGenx Technologies Corp., Kaken Pharmaceutical Co.,Ltd., Karo Bio, Nymox Pharmaceutical Corporation, Quest PharmaTech Inc., Plethora Solutions Holdings plc, Protox Therapeutics Inc., AndroScience Corporation, NovaLead Pharma Pvt. Ltd., EndoCeutics, Inc., AmVac AG, KAEL-GemVax, Ausio Pharmaceuticals, LLC, Se-cure Pharmaceuticals Ltd.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Benign Prostatic Hyperplasia - Pipeline Review, H1 2013
- Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2012
- Erectile Dysfunction - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013
- Influenza - Pipeline Review, H2 2013